PyInvesting

Market research

RB0.F REGENXBIO Inc

F EUR Healthcare

Latest close

6.642 —

As of Nov 19, 2026

Test a moving-average rule with historical data.

Market facts

Market cap
434M
P/E ratio
Not available
Analyst target
65.13
Dividend yield
Not available
Beta
1.23

Community

Investor discussion

1 comment

Admin profile picture
Admin

Apr 1, 2021

REGENXBIO Inc is currently in a long term uptrend where the price is trading 0.9% above its 200 day moving average.

From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.2.

REGENXBIO Inc's total revenue rose by 82.2% to $21M since the same quarter in the previous year.

Its net income has dropped by 74.7% to $-46M since the same quarter in the previous year.

Finally, its free cash flow grew by 200.2% to $27M since the same quarter in the previous year.

Based on the above factors, REGENXBIO Inc gets an overall score of 4/5.